Results 41 to 50 of about 466,931 (209)

Pediatric Pulmonary Hypertension

Journal of the American College of Cardiology, 2013
Pulmonary hypertension (PH) is a rare disease in newborns, infants, and children that is associated with significant morbidity and mortality. In the majority of pediatric patients, PH is idiopathic or associated with congenital heart disease and rarely is associated with other conditions such as connective tissue or thromboembolic disease.
Ivy, D Dunbar, Abman, Steven H, Barst, Robyn J, Berger, Rolf M F, Bonnet, Damien, Fleming, Thomas R, Haworth, Sheila G, Raj, J Usha, Rosenzweig, Erika B, Schulze Neick, Ingram, Steinhorn, Robin H, Beghetti, Maurice   +11 more
openaire   +5 more sources

P297 Left atrial volume index is the best predictor of post-capillary pulmonary hypertension in patients with pure mitral valve stenosis [PDF]

, 2020
Ciro Santoro, Marcello Esposito, Raffaella Sorrentino, Maria Lembo, Roberta Esposito, V Sellitto, Federica Luciano, Maurizio Galderisi   +7 more
openalex   +1 more source

PULMONARY ARTERIAL HYPERTENSION

Annals of Medicine, 2006
Pulmonary arterial hypertension is a disease of the small pulmonary arteries characterized by vascular narrowing and increased pulmonary vascular resistance, which eventually leads to right ventricular failure. Vasoconstriction, vascular proliferation, remodeling of the pulmonary vessels, and thrombosis are all contributing factors to the increased ...
Azad, Raiesdana, Joseph, Loscalzo
openaire   +2 more sources

Safety, tolerability, and efficacy of an in‐class combination therapy switch from bosentan plus sildenafil to ambrisentan plus tadalafil in children with pulmonary arterial hypertension

Pulmonary Circulation
The aim of this single‐centre retrospective observational study was to evaluate the safety, tolerability, and efficacy of an in‐class combination therapy switch from bosentan plus sildenafil to ambrisentan plus tadalafil in children with pulmonary ...
Cara Morgan, Nikmah Idris, Kathy Elterefi, Luca Di Ienno, Andrew Constantine, Sadia Quyam, Roberta Bini, Shahin Moledina   +7 more
doaj   +1 more source

Low DLCO Can Provide Insights into Treatment Response in PAH Patients Irrespective of the Reason for Its Decrease

Life
Group 1 of PAH patients encompasses patients with a diverse underlying etiological condition, having histological modifications that can affect gas exchange across the alveolar-capillary membrane, as reflected by decreased DLCO.
Effrosyni Dima, Stylianos E. Orfanos, Vasileios Grigoropoulos, Dimitra Fasfali, Athina Mpatsouli, Natalia P. Zimpounoumi-Keratsa, Panagioula Niarchou, Athanasia Megarisiotou, Efstathia Prappa, Sotirios Xydonas, Anastasia Kotanidou, Ioanna Dimopoulou, Anastasia Anthi   +12 more
doaj   +1 more source

Exploring the Endothelin-1 pathway in chronic thromboembolic pulmonary hypertension microvasculopathy

Scientific Reports
Targeted vasopeptide therapies have significantly advanced the management of pulmonary arterial hypertension (PAH). However, due to insufficient preclinical evidence regarding the involvement of the endothelin-1 (ET-1) pathway in chronic thromboembolic ...
Benchenouf Feriel, Cuomo Alessandra, Gorth J. Deborah, Normand Corinne, Thuillet Raphaël, Ottaviani Mina, Akamkam Ali, Menager Jean-Baptiste, Fadel Guillaume, Grynblat Julien, Ghigna Maria-Rosa, Fadel Elie, Savale Laurent, Mercier Olaf, Tu Ly, Humbert Marc, Guignabert Christophe   +16 more
doaj   +1 more source

DDAH1 regulates apoptosis and angiogenesis in human fetal pulmonary microvascular endothelial cells

Physiological Reports, 2019
Nitric Oxide (NO) is an endogenous pulmonary vasodilator produced by endothelial NO synthase (eNOS). Asymmetric dimethyl L‐arginine (ADMA) is an endogenous inhibitor of eNOS activity.
Jennifer K. Trittmann, Hanadi Almazroue, Yi Jin, Leif D. Nelin   +3 more
doaj   +1 more source

Pulmonary Hypertension Caused by Pulmonary Venous Hypertension [PDF]

Pulmonary Circulation, 2014
The effect of pulmonary venous hypertension (PVH) on the pulmonary circulation is extraordinarily variable, ranging from no impact on pulmonary vascular resistance (PVR) to a marked increase. The reasons for this are unknown. Both acutely reversible pulmonary vasoconstriction and pathological remodeling (especially medial hypertrophy and intimal ...
openaire   +3 more sources

Sarcopenia in Patients with Chronic Thromboembolic Pulmonary Hypertension

Journal of Cardiovascular Development and Disease
Background: Sarcopenia, or loss of skeletal muscle mass, has been associated with poor outcomes (e.g., functional decline, increased mortality, and low quality of life), but its role in CTEPH remains unclear.
Steven Hopkins, Jillian Hall, Hollie Saunders, Riyaz Bashir, Vladimir Lakhter, Anjali Vaidya, Ahmed Sadek, Paul Forfia, Estefania Oliveros   +8 more
doaj   +1 more source

Pulmonary hypertension

Swiss Medical Weekly, 2003
Pulmonary arterial hypertension (PAH) must be classified into primary pulmonary hypertension and PAH related to other diseases such as collagen vascular diseases, HIV infection or portal hypertension. PAH must also be differentiated from other entities, in particular pulmonary hypertension secondary to thromboembolic diseases, requiring specific ...
openaire   +3 more sources